Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Egetis Therapeutics in connection with directed share issuances
Mandate

Vinge has advised Egetis Therapeutics in connection with directed share issuances

October 03, 2024

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.

The share issuances were directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is subject to approval by an extraordinary general meeting as well as approval and publication of a prospectus.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 505 million

 Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 505 million before transaction costs.
October 25, 2024

Vinge advises Main Capital and Aunetic in connection with the acquisition of Qnister

 Vinge has advised Aunetic, a leading governance software specialist, in connection with the acquisition of Qnister AB (“Qnister”). The strategic acquisition enhances Aunetic’s product portfolio and strengthens its presence in the Swedish software compliance market.
October 25, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024